Sanofi (SNY) Stock Forecast & Price Target

Compare

2,192 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SNY Analyst Ratings

Moderate Buy

2 Buy

3 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Sanofi

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SNY Stock 12 Month Forecast

Average Price Target

$78.96

▲(68.86% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Sanofi in the last 3 months. The average price target is $78.96 with a high forecast of $117.89 and a low forecast of $57.00. The average price target represents a 68.86% change from the last price of $46.76.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"45":"$45","118":"$118","63.25":"$63.3","81.5":"$81.5","99.75":"$99.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":117.89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$117.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":78.96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$78.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$57.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[45,63.25,81.5,99.75,118],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.27,52.7023076923077,58.13461538461539,63.56692307692308,68.99923076923078,74.43153846153847,79.86384615384617,85.29615384615386,90.72846153846154,96.16076923076923,101.59307692307692,107.02538461538462,112.45769230769233,{"y":117.89,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.27,49.70769230769231,52.145384615384614,54.58307692307692,57.02076923076923,59.458461538461535,61.896153846153844,64.33384615384615,66.77153846153846,69.20923076923077,71.64692307692307,74.08461538461538,76.52230769230769,{"y":78.96,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.27,48.018461538461544,48.76692307692308,49.51538461538462,50.26384615384615,51.012307692307694,51.760769230769235,52.50923076923077,53.25769230769231,54.00615384615385,54.754615384615384,55.503076923076925,56.25153846153846,{"y":57,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":52.662,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.788,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.662,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.19,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.05,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.75,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.58,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.46,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.27,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$117.89

Average Price Target$78.96

Lowest Price Target$57.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Steve Scala

TD Cowen

$57

Hold

21.90%

Upside

Reiterated

02/19/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Ocular Therapeutix (NASDAQ: OCUL) and Sanofi (NASDAQ: SNY)We met with Sanofi's CFO yesterday in Boston and discussed a wide range of topics. This note summarizes the highlights. Separately, we have updated our model post Q4 results and other recent news. CEO Management noted CEO transition followed a deliberate Board review of what the company has achieved under Sanofi's outgoing CEO and what is required to succeed in the next decade. Under outgoing leadership, the company successfully commercialized a mega-blockbuster brand in Dupixent, delivered consistent profitable growth, and meaningfully streamlined the company's manufacturing footprint. Conversely, R&D output, scientific rigor, and better transparency were identified as areas which could benefit from fresh leadership.

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

$62

Buy

32.59%

Upside

Reiterated

01/20/26

Berenberg Bank Keeps Their Buy Rating on Sanofi (SNY)

Emily Field

Barclays

―

Hold

―

Downgraded

01/06/26

Sanofi downgraded to Equal Weight from Overweight at BarclaysSanofi downgraded to Equal Weight from Overweight at Barclays

Seamus Fernandez

Guggenheim

―

Hold

―

Downgraded

12/09/25

Sanofi downgraded to Neutral from Buy at GuggenheimSanofi downgraded to Neutral from Buy at Guggenheim

Rajesh Kumar

HSBC

$120.25→$117.89

Buy

152.12%

Upside

Reiterated

12/02/25

Sarita Kapila

Morgan Stanley

$56→$58

Buy

24.04%

Upside

Upgraded

09/08/25

Sanofi upgraded to Overweight from Equal Weight at Morgan StanleySanofi upgraded to Overweight from Equal Weight at Morgan Stanley

David Risinger

Leerink Partners

―

Buy

―

Reiterated

09/04/25

Leerink Partners Sticks to Their Buy Rating for Sanofi (SNY)

James Quigley

Goldman Sachs

$67→$60

Hold

28.31%

Upside

Reiterated

07/03/25

Analysts' Top Healthcare Picks: Sanofi (SNY), RxSight (RXST)

Nico Chen

DBS

$66

Buy

41.15%

Upside

Reiterated

06/03/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Steve Scala

TD Cowen

$57

Hold

21.90%

Upside

Reiterated

02/19/26

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

$62

Buy

32.59%

Upside

Reiterated

01/20/26

Berenberg Bank Keeps Their Buy Rating on Sanofi (SNY)

Emily Field

Barclays

―

Hold

―

Downgraded

01/06/26

Sanofi downgraded to Equal Weight from Overweight at BarclaysSanofi downgraded to Equal Weight from Overweight at Barclays

Seamus Fernandez

Guggenheim

―

Hold

―

Downgraded

12/09/25

Sanofi downgraded to Neutral from Buy at GuggenheimSanofi downgraded to Neutral from Buy at Guggenheim

Rajesh Kumar

HSBC

$120.25→$117.89

Buy

152.12%

Upside

Reiterated

12/02/25

Sarita Kapila

Morgan Stanley

$56→$58

Buy

24.04%

Upside

Upgraded

09/08/25

Sanofi upgraded to Overweight from Equal Weight at Morgan StanleySanofi upgraded to Overweight from Equal Weight at Morgan Stanley

David Risinger

Leerink Partners

―

Buy

―

Reiterated

09/04/25

Leerink Partners Sticks to Their Buy Rating for Sanofi (SNY)

James Quigley

Goldman Sachs

$67→$60

Hold

28.31%

Upside

Reiterated

07/03/25

Analysts' Top Healthcare Picks: Sanofi (SNY), RxSight (RXST)

Nico Chen

DBS

$66

Buy

41.15%

Upside

Reiterated

06/03/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sanofi

3 Months

xxx

Success Rate

3/3 ratings generated profit

Average Return

+0.70%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +0.70% per trade.

1 Year

Google Drug Manufacturers - GeneralTipRanks - Google

Success Rate

1/2 ratings generated profit

Average Return

-2.85%

reiterated a buy rating 25 days ago

Copying Google Drug Manufacturers - General's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -2.85% per trade.

2 Years

xxx

Success Rate

1/2 ratings generated profit

Average Return

-2.85%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -2.85% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SNY Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SNY has received 4 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. SNY average Analyst price target in the past 3 months is 78.96.

Each month's total comprises the sum of three months' worth of ratings.

SNY Financial Forecast

SNY Earnings Forecast

Next quarter’s earnings estimate for SNY is $1.05 with a range of $0.95 to $1.10. The previous quarter’s EPS was $0.91. SNY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year SNY has Performed in-line its overall industry.

SNY Sales Forecast

Next quarter’s sales forecast for SNY is $12.47B with a range of $11.74B to $12.83B. The previous quarter’s sales results were $27.68B. SNY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year SNY has Performed in-line its overall industry.

SNY Stock Forecast FAQ

What is SNY’s average 12-month price target, according to analysts?

Based on analyst ratings, Sanofi SA’s 12-month average price target is 78.96.

What is SNY’s upside potential, based on the analysts’ average price target?

Sanofi SA has 68.86% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SNY a Buy, Sell or Hold?

Sanofi SA has a consensus rating of Moderate Buy which is based on 2 buy ratings, 3 hold ratings and 0 sell ratings.

What is Sanofi SA’s price target?

The average price target for Sanofi SA is 78.96. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $117.89 ,the lowest forecast is $57.00. The average price target represents 68.86% Increase from the current price of $46.76.

What do analysts say about Sanofi SA?

Sanofi SA’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of SNY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Sanofi (SNY) Stock Forecast & Price Target

SNY Analyst Ratings

SNY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sanofi

SNY Analyst Recommendation Trends

SNY Financial Forecast

SNY Earnings Forecast

SNY Sales Forecast

SNY Stock Forecast FAQ

Detailed List of Analyst Forecasts